AVTE NASDAQ
Aerovate Therapeutics, Inc.
1W: -3.2%
1M: +5.9%
3M: +4.3%
1Y: -87.4%
3Y: -82.0%
$2.68
Last traded 2025-04-28 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$77.7M
52W Range2.6296-884.975
Volume981,795
Avg Volume7,993
Beta0.95
Dividend—
Analyst Ratings
Company Info
CEOTimothy P. Noyes
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-30
Websiteaerovatetx.com
930 Winter Street
Waltham, MA 02116
US
Waltham, MA 02116
US
617 443 2400
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dake Benjamin T | M-Exempt | 1,507 | $1.74 | 2024-08-01 |
| Dake Benjamin T | M-Exempt | 1,507 | $1.74 | 2024-08-01 |
| Dake Benjamin T | M-Exempt | 11,454 | $1.74 | 2024-07-31 |
| Dake Benjamin T | M-Exempt | 10,548 | $1.74 | 2024-07-31 |
| RA CAPITAL MANAGEMEN | P-Purchase | 928,110 | $1.67 | 2024-06-17 |